LON:VAL ValiRx (VAL) Share Price, News & Analysis GBX 0.75 +0.20 (+36.36%) As of 06/20/2025 11:55 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ValiRx Stock (LON:VAL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ValiRx alerts:Sign Up Key Stats Today's Range 0.60▼ 0.8850-Day Range 0.46▼ 0.7552-Week Range 0.38▼ 3.50Volume43.35 million shsAverage Volume6.47 million shsMarket Capitalization£2.85 millionP/E RatioN/ADividend Yield0.63%Price TargetN/AConsensus RatingN/A Company OverviewValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.Read More… Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VAL Stock News HeadlinesValiRx signs licence with Ambrose worth GBP16 million plus royaltiesJune 20 at 12:47 PM | lse.co.ukValiRx subsidiary enters evaluation agreement with Omios BiologicsJune 3, 2025 | lse.co.ukNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.June 21, 2025 | American Alternative (Ad)ValiRx Expands Cancer Therapeutics Through Strategic PartnershipsApril 30, 2025 | tipranks.comValiRx shares fall as ends collaboration with Imperial College LondonFebruary 25, 2025 | lse.co.ukValiRx PLC Reports Change in Major Shareholder HoldingsJanuary 2, 2025 | tipranks.comValiRx plc Announces Change in Major ShareholdingsDecember 31, 2024 | tipranks.comAIM WINNERS & LOSERS: Strong 2024 for Quadrise and RosebankDecember 31, 2024 | lse.co.ukSee More Headlines VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed this year? ValiRx's stock was trading at GBX 0.65 at the beginning of the year. Since then, VAL stock has increased by 15.4% and is now trading at GBX 0.75. View the best growth stocks for 2025 here. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) announced its quarterly earnings results on Friday, June, 6th. The company reported ($1.45) EPS for the quarter. ValiRx had a negative trailing twelve-month return on equity of 55.84% and a negative net margin of 20,554.01%. How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Lloyds Banking Group (LLOY), IQE (IQE) and Scirocco Energy Plc (SOLO.L) (SOLO). Company Calendar Last Earnings6/06/2025Today6/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPetroleum And Natural Gas Current SymbolLON:VAL CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees5,450Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.71 million Net Margins-20,554.01% Pretax MarginN/A Return on Equity-55.84% Return on Assets-35.98% Debt Debt-to-Equity Ratio0.44 Current Ratio6.65 Quick Ratio1.27 Sales & Book Value Annual Sales£27.78 thousand Price / Sales102.50 Cash FlowGBX 0.01 per share Price / Cash Flow62.50 Book ValueGBX 2.67 per share Price / Book0.28Miscellaneous Outstanding Shares379,605,148Free FloatN/AMarket Cap£2.85 million OptionableNot Optionable Beta0.59 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (LON:VAL) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ValiRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.